Clinical evaluation of a new recombinant antigen-based cytomegalovirus immunoglobulin M immunoassay in liver transplant recipients

Valerie W. Halling, Gregory T. Maine, Cindy M. Groettum, Jean A. Wilson, Jack Spesard, Susan Brojanac, Brad Combs, Dawnell Wachta, Cindy Holas, Tracy Wilson, Di Wang, Susan Tomazic-Allen, Tiziana Lazzarotto, Maria Paola Landini, Svetlena Jevremovic-Simovic, Russell H. Wiesner, Carlos V. Paya, Thomas F. Smith

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background. Human cytomegalovirus (CMV) is a significant cause of morbidity and mortality among transplant recipients. Monitoring transplant recipients by CMV IgM serology has been questioned by several studies due to the reported insensitivity of serologic tests relative to antigen detection methods. Methods. In this retrospective study, we have evaluated the performance of the new recombinant antigen-based Abbott AxSYM CMV IgM assay and compared it with CMV culture technique in a cohort of 40 liver transplant recipients who did not receive antiviral prophylaxis. Results. The sensitivity, specificity, and positive and negative predictive values for detection of CMV disease by the AxSYM CMV IgM assay were 90.0%, 60.0%, 69.2%, and 85.7%, respectively, and by culture the values were 100%, 55.0%, 69.0%, and 100%, respectively. Detection of CMV IgM occurred before or at the time of CMV disease in only R+ recipients. Conclusion. Although this assay is a sensitive test for CMV-specific IgM, detection of CMV IgM preceded detection of virus by culture in patients only when the liver transplant recipient was CMV immune before transplantation (R+).

Original languageEnglish (US)
Pages (from-to)395-397
Number of pages3
JournalTransplantation
Volume71
Issue number3
StatePublished - Feb 15 2001

Fingerprint

Cytomegalovirus
Immunoassay
Immunoglobulin M
Antigens
Liver
Transplant Recipients
Culture Techniques
Serologic Tests
Serology
Antiviral Agents
Retrospective Studies
Transplantation
Viruses
Morbidity
Sensitivity and Specificity
Mortality

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Halling, V. W., Maine, G. T., Groettum, C. M., Wilson, J. A., Spesard, J., Brojanac, S., ... Smith, T. F. (2001). Clinical evaluation of a new recombinant antigen-based cytomegalovirus immunoglobulin M immunoassay in liver transplant recipients. Transplantation, 71(3), 395-397.

Clinical evaluation of a new recombinant antigen-based cytomegalovirus immunoglobulin M immunoassay in liver transplant recipients. / Halling, Valerie W.; Maine, Gregory T.; Groettum, Cindy M.; Wilson, Jean A.; Spesard, Jack; Brojanac, Susan; Combs, Brad; Wachta, Dawnell; Holas, Cindy; Wilson, Tracy; Wang, Di; Tomazic-Allen, Susan; Lazzarotto, Tiziana; Landini, Maria Paola; Jevremovic-Simovic, Svetlena; Wiesner, Russell H.; Paya, Carlos V.; Smith, Thomas F.

In: Transplantation, Vol. 71, No. 3, 15.02.2001, p. 395-397.

Research output: Contribution to journalArticle

Halling, VW, Maine, GT, Groettum, CM, Wilson, JA, Spesard, J, Brojanac, S, Combs, B, Wachta, D, Holas, C, Wilson, T, Wang, D, Tomazic-Allen, S, Lazzarotto, T, Landini, MP, Jevremovic-Simovic, S, Wiesner, RH, Paya, CV & Smith, TF 2001, 'Clinical evaluation of a new recombinant antigen-based cytomegalovirus immunoglobulin M immunoassay in liver transplant recipients', Transplantation, vol. 71, no. 3, pp. 395-397.
Halling VW, Maine GT, Groettum CM, Wilson JA, Spesard J, Brojanac S et al. Clinical evaluation of a new recombinant antigen-based cytomegalovirus immunoglobulin M immunoassay in liver transplant recipients. Transplantation. 2001 Feb 15;71(3):395-397.
Halling, Valerie W. ; Maine, Gregory T. ; Groettum, Cindy M. ; Wilson, Jean A. ; Spesard, Jack ; Brojanac, Susan ; Combs, Brad ; Wachta, Dawnell ; Holas, Cindy ; Wilson, Tracy ; Wang, Di ; Tomazic-Allen, Susan ; Lazzarotto, Tiziana ; Landini, Maria Paola ; Jevremovic-Simovic, Svetlena ; Wiesner, Russell H. ; Paya, Carlos V. ; Smith, Thomas F. / Clinical evaluation of a new recombinant antigen-based cytomegalovirus immunoglobulin M immunoassay in liver transplant recipients. In: Transplantation. 2001 ; Vol. 71, No. 3. pp. 395-397.
@article{229a918b5e68437b858451b167786e1d,
title = "Clinical evaluation of a new recombinant antigen-based cytomegalovirus immunoglobulin M immunoassay in liver transplant recipients",
abstract = "Background. Human cytomegalovirus (CMV) is a significant cause of morbidity and mortality among transplant recipients. Monitoring transplant recipients by CMV IgM serology has been questioned by several studies due to the reported insensitivity of serologic tests relative to antigen detection methods. Methods. In this retrospective study, we have evaluated the performance of the new recombinant antigen-based Abbott AxSYM CMV IgM assay and compared it with CMV culture technique in a cohort of 40 liver transplant recipients who did not receive antiviral prophylaxis. Results. The sensitivity, specificity, and positive and negative predictive values for detection of CMV disease by the AxSYM CMV IgM assay were 90.0{\%}, 60.0{\%}, 69.2{\%}, and 85.7{\%}, respectively, and by culture the values were 100{\%}, 55.0{\%}, 69.0{\%}, and 100{\%}, respectively. Detection of CMV IgM occurred before or at the time of CMV disease in only R+ recipients. Conclusion. Although this assay is a sensitive test for CMV-specific IgM, detection of CMV IgM preceded detection of virus by culture in patients only when the liver transplant recipient was CMV immune before transplantation (R+).",
author = "Halling, {Valerie W.} and Maine, {Gregory T.} and Groettum, {Cindy M.} and Wilson, {Jean A.} and Jack Spesard and Susan Brojanac and Brad Combs and Dawnell Wachta and Cindy Holas and Tracy Wilson and Di Wang and Susan Tomazic-Allen and Tiziana Lazzarotto and Landini, {Maria Paola} and Svetlena Jevremovic-Simovic and Wiesner, {Russell H.} and Paya, {Carlos V.} and Smith, {Thomas F.}",
year = "2001",
month = "2",
day = "15",
language = "English (US)",
volume = "71",
pages = "395--397",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Clinical evaluation of a new recombinant antigen-based cytomegalovirus immunoglobulin M immunoassay in liver transplant recipients

AU - Halling, Valerie W.

AU - Maine, Gregory T.

AU - Groettum, Cindy M.

AU - Wilson, Jean A.

AU - Spesard, Jack

AU - Brojanac, Susan

AU - Combs, Brad

AU - Wachta, Dawnell

AU - Holas, Cindy

AU - Wilson, Tracy

AU - Wang, Di

AU - Tomazic-Allen, Susan

AU - Lazzarotto, Tiziana

AU - Landini, Maria Paola

AU - Jevremovic-Simovic, Svetlena

AU - Wiesner, Russell H.

AU - Paya, Carlos V.

AU - Smith, Thomas F.

PY - 2001/2/15

Y1 - 2001/2/15

N2 - Background. Human cytomegalovirus (CMV) is a significant cause of morbidity and mortality among transplant recipients. Monitoring transplant recipients by CMV IgM serology has been questioned by several studies due to the reported insensitivity of serologic tests relative to antigen detection methods. Methods. In this retrospective study, we have evaluated the performance of the new recombinant antigen-based Abbott AxSYM CMV IgM assay and compared it with CMV culture technique in a cohort of 40 liver transplant recipients who did not receive antiviral prophylaxis. Results. The sensitivity, specificity, and positive and negative predictive values for detection of CMV disease by the AxSYM CMV IgM assay were 90.0%, 60.0%, 69.2%, and 85.7%, respectively, and by culture the values were 100%, 55.0%, 69.0%, and 100%, respectively. Detection of CMV IgM occurred before or at the time of CMV disease in only R+ recipients. Conclusion. Although this assay is a sensitive test for CMV-specific IgM, detection of CMV IgM preceded detection of virus by culture in patients only when the liver transplant recipient was CMV immune before transplantation (R+).

AB - Background. Human cytomegalovirus (CMV) is a significant cause of morbidity and mortality among transplant recipients. Monitoring transplant recipients by CMV IgM serology has been questioned by several studies due to the reported insensitivity of serologic tests relative to antigen detection methods. Methods. In this retrospective study, we have evaluated the performance of the new recombinant antigen-based Abbott AxSYM CMV IgM assay and compared it with CMV culture technique in a cohort of 40 liver transplant recipients who did not receive antiviral prophylaxis. Results. The sensitivity, specificity, and positive and negative predictive values for detection of CMV disease by the AxSYM CMV IgM assay were 90.0%, 60.0%, 69.2%, and 85.7%, respectively, and by culture the values were 100%, 55.0%, 69.0%, and 100%, respectively. Detection of CMV IgM occurred before or at the time of CMV disease in only R+ recipients. Conclusion. Although this assay is a sensitive test for CMV-specific IgM, detection of CMV IgM preceded detection of virus by culture in patients only when the liver transplant recipient was CMV immune before transplantation (R+).

UR - http://www.scopus.com/inward/record.url?scp=0035865242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035865242&partnerID=8YFLogxK

M3 - Article

VL - 71

SP - 395

EP - 397

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 3

ER -